Vaccine Failures, Part 2: Pertussis Vaccination

By the Children’s Health Defense Team

[Note: This is the second in a series of articles examining the serious problem of vaccine failure—a problem that, scandalously, remains unacknowledged by the public health officials and politicians promoting draconian vaccine mandates. Part 1 examined the measles vaccination.]

Over the past decade, an average of over 25,000 cases of pertussis (the respiratory illness also known as “whooping cough”) has been reported to the CDC annually. The CDC made no mention of pertussis in its round-up of “nine health threats that made headlines in 2019” (whereas 1,276 non-fatal cases of measles made the list), but, judging from news reports, 2019 was another banner year for pertussis—especially in the vaccinated. And, as numerous peer-reviewed studies published in the past few years show, the blame must be laid squarely at the feet of a fatally flawed vaccination program that is making vaccinated children more rather than less susceptible to pertussis over their lifetimes.

Pertussis vaccination targets the Bordetella pertussis (B. pertussis) organism, a “fastidious” bacterial pathogen spread by respiratory droplets. Nationally, pertussis-containing vaccine coverage is high—just shy of 95%—yet, by the CDC’s own admission, pertussis outbreaks are increasingly frequent. In addition, many cases of pertussis go undiagnosed and, therefore, unreported, with an estimated ratio of up to 1,400 undocumented pertussis infections for every recorded case. Given the high vaccination rate and the known fact that vaccinated persons can transmit pertussis asymptomatically (see Failure #4), it is important to dissect the spectacular failure of U.S. pertussis vaccination efforts in greater detail.

Failure #1: In the U.S., children and adults who receive pertussis-containing vaccines, immunity wanes rapidly—a fact known and reiterated for years.

In the U.S., the CDC’s childhood vaccine schedule includes five doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine at two, four, six and 15-18 months and 4-6 years, followed by a dose of tetanus-diphtheria-acellular pertussis (Tdap) vaccine at age 11 or 12 and more Tdap boosters in adulthood. (The CDC also recommends “off-license” administration of a Tdap dose to pregnant women during each pregnancy.) Numerous studies (both recent and not-so-recent) indicate that this dose-intensive vaccination regimen—far from providing meaningful protection—may actually be facilitating pertussis outbreaks.

Waning immunity (also called secondary vaccine failure) is one of the leading factors contributing to the pertussis fiasco. Top vaccine experts have been surprisingly frank in admitting this major shortcoming:

• In 2017, Dr. Stanley Plotkin, the well-known vaccine developer (and former medical and scientific director of Sanofi Pasteur) who consults for vaccine manufacturers, wrote about the rapid waning of pertussis vaccines, stating that vaccine effectiveness drops off “as early as 2-3 years post-boosters.” Plotkin and his two coauthors (one affiliated with Sanofi) pointed to a record-breaking 2010 pertussis outbreak in California that witnessed high disease rates in fully vaccinated preadolescents; two-thirds (66%) of the cases in fully vaccinated children were in 7- to 10-year-olds—that is, children not far removed from their fifth dose of DTaP. The trio of authors conceded that current pertussis vaccines provide inferior immunity compared to the “rather robust” immunity induced by natural pertussis infection.
• Another 2017 study, this time by Kaiser Permanente and GlaxoSmithKline authors, reported that not only does pertussis vaccine effectiveness wane substantially after the fifth dose—falling, by their estimate, an average of 27% per year—but waning occurs with all DTaP brands on the market. In a different study, some of the same Kaiser researchers pronounced waning DTaP immunity to be an “important cause of pertussis” in age-appropriately vaccinated children over 18 months of age.
• A 2016 study by a consortium of Canadian scientists described the rapid decline in pertussis vaccine effectiveness—notably at around the four-year mark since last vaccination.

Failure #2: Pertussis outbreaks are frequent, and the majority of cases are occurring in the vaccinated.

In early 2019, news outlets covered a pertussis outbreak at an elite, 1,600-student private high school in Los Angeles. Notwithstanding a “really high vaccination rate,” 30 students—all vaccinated—developed pertussis, whereas none of the high school’s unvaccinated students (18 students with medical exemptions) contracted the infection. School officials even emphasized that the outbreak could not be attributed to the unvaccinated students. That same month, a UCLA researcher (one of the nation’s top authorities on pertussis vaccination) characterized the increased lifetime susceptibility to pertussis faced by DTaP-vaccinated children as a conundrum with no easy solution.

A study in Pediatrics that followed in July 2019 reported that 82% of pediatric pertussis cases identified by Kaiser Permanente California were in children who had been fully vaccinated (including 12% “fully vaccinated plus 1 dose”), and another 5% of cases occurred in partially pertussis-vaccinated children. From ages one and a half to seven years, vaccinated children’s pertussis risk quintupled once three or more years had elapsed since vaccination.

Capping off 2019, a Catholic school and daycare center in Houston—where 100% of the students were vaccinated—was forced to close early for the Christmas holidays due to a pertussis outbreak. In a letter to parents, the principal and school pastor stated that “Doctors are unsure why vaccinated children may still get the disease,” but news reports zeroed in on waning immunity as the likely culprit.

Failure #3: Pertussis risks are significant in infants but are also shifting toward adolescence and adulthood.

Pertussis incidence is high in infants. From 2000 through 2016 (a period of time in which pertussis incidence “increased significantly” across the U.S.), infants in their first year of life represented 15% of cases—with incidence anywhere from 4 to 63 times higher than for other age groups. Infants also had the highest hospitalization rate and accounted for 89% of deaths. However, another 60% of cases were in children: 32% in those aged 1-10 years and 28% in preadolescents and adolescents (ages 11-18).

At the same time, some researchers are describing a shift in the burden of pertussis toward adolescents and young adults as well as older adults. In one managed care setting, 59% of cases from 2006-2015 were in adolescents or adults. These shifts have implications in terms of both pertussis severity and health care costs. For example, while adults 65 years of age or older represented just 2.4% of U.S. pertussis cases between 2000-2016, these older adults constituted 14% of pertussis-related hospitalizations and 5% of deaths. Average charges for inpatient care for a pertussis episode in an older adult are significant—over $14,000 per patient. A recent study confirms that the clinical management of thousands of pertussis cases annually “is associated with substantial economic burden,” especially in patients from the two most vulnerable age groups—infants and older adults.

Failure #4: Asymptomatic vaccinated individuals are a major source of B. pertussis transmission.

A number of studies have suggested that “vaccinated individuals may harbor and transmit [pertussis] infection, even in the absence of typical pertussis symptoms.” In a 2020 systematic review, the authors conclude that “the prevalence of asymptomatic infection is high” and that “frequent close contact occurring in household settings may provide sufficient opportunity for B. pertussis to spread.”

In 2015, an article in BMC Medicine made a similar case, asserting that asymptomatic transmission by pertussis-vaccinated individuals to their close contacts provides “the most parsimonious explanation for many of the observations surrounding the resurgence of B. pertussis” in the United States as well as the United Kingdom. Drawing out various implications for pertussis vaccination policy, the authors commented that asymptomatic transmission:

• Can account for the increase in pertussis incidence
• Is consistent with the timing of changes in age-specific pertussis attack rates
• May be biasing assessments of vaccine efficacy

The BMC Medicine authors also noted the likely futility of “vaccinating individuals in close contact with infants too young to receive the vaccine” (so-called “cocooning”). In fact, in light of studies suggesting that subclinically infected adults are the most likely source of transmission to infants, it seems possible that cocooning could increase rather than decrease risks for the very youngest.

Failure #5: Subclinical pertussis infection is linked to other serious health risks.

In their 2017 article on waning immunity, Stanley Plotkin and coauthors noted that acellular-pertussis-containing vaccines are less effective than either natural infection or the more dangerous whole-cell-pertussis vaccines (no longer in use in the U.S.) in staving off B. pertussis colonization of the nasopharynx; other researchers concur that subclinical nasopharyngeal colonization by B. pertussis is common in highly vaccinated populations. An emerging and disturbing area of research links asymptomatic B. pertussis colonization to the development in the host of serious conditions such as epilepsy, multiple sclerosis (MS) and even Alzheimer’s disease. The researchers making this case for MS (who are developing a new pertussis vaccine) refer to the half-century-old observation that “The epidemiological features of multiple sclerosis are compatible with the hypothesis that the clinical illness may be an occasional manifestation of a widespread subclinical infection.”

Failure #6: Today’s pertussis vaccines are not keeping up with bacterial mutations.

In the midst of the numerous 2019 pertussis outbreaks, USA Today reported on CDC research suggesting that today’s whooping cough “is being battled by yesterday’s vaccine” as a result of growing vaccine resistance—or what researchers call “adaptation of B. pertussis to vaccine selection pressure.” In 2014, CDC researchers reported a dramatic increase in mutated B. pertussis isolates all over the U.S., with the mutated isolates representing more than 50% of collected isolates in 2012—a year in which U.S. pertussis cases spiked to over 48,000 (a 157% increase over 2011). The CDC Pertussis Working Group later acknowledged the need to study circulating genotypes that diverge “from existing laboratory and vaccine reference strains” and assess whether they alter antigen expression and lead to changes in the burden of disease.

Studies also show that infections triggered by another Bordetella pathogen called B. parapertussis are becoming more common around the world and are affecting “mainly vaccinated populations.” Because B. parapertussis has mechanisms that allow it to “evade the immune response induced by pertussis vaccines,” the incidence of B. parapertussis infection increased after the introduction of acellular pertussis vaccines. A study of pertussis infections in Massachusetts from 1990 through 2008 found that one in ten cases were due to B. parapertussis, with most cases in precisely the 5- to 10-year age group “expected to have strong vaccine-induced immunity.” Other studies have confirmed that existing pertussis vaccines “are not protective against disease induced by B. parapertussis.”

Failure #7: Doctors and public health officials are not being forthright about vaccine failure.

In a commentary on the 2019 pertussis outbreaks, investigative reporter Sharyl Attkisson raises pertinent questions of disclosure and informed consent, asking whether doctors who administer pertussis vaccines are “disclosing to parents that the whooping cough protection will only last a relatively short time” and that middle school boosters are “probably only effective for about a year”? Atkisson’s point about incomplete disclosure and inadequate informed consent applies to virtually all vaccines recommended for children and adults. However, as Atkisson concludes, the obfuscation of important information about vaccine failures is convenient for the “power brokers” who “continue making money without improving the product through technologically possible advances.”

Further reading from the Children’s Health Defense website:

May 31, 2019: Pertussis: Vaccine Failure, not Failure to Vaccinate
May 28, 2019: The California Senate Voted to Give Your Child Whooping Cough
May 7, 2019: Most of You Think We Know What Our Vaccines Are Doing—We Don’t
March 6, 2019: Failure to Vaccinate or Vaccine Failure: What Is Driving Disease Outbreaks?
August 17, 2018: Study Claims Tdap Vaccine in Pregnancy Doesn’t Cause Autism—Is that True Given the Facts?
July 31, 2018: One in Nine Adverse Events Reported After DTaP Vaccination Is Serious—But CDC Says, “Don’t Worry, Be Happy”
April 24, 2017: DTP Vaccine Increases Mortality in Young Infants 5 to 10-Fold Compared to Unvaccinated Infants

The post Vaccine Failures, Part 2: Pertussis Vaccination appeared first on Children's Health Defense.

© 09 Jan 2020 Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.